GSE137719
ATAC-seq profiling assessing the impact of IFNg and Pictilisib on human SqCC/Y1 cells
To examine differences in chromatin accessibility SqCC/Y1 cells were treated with Pictilisib to inhibit PI3K signaling in combination with DMSO or IFNg for 48 hours and ATAC-seq performed. Overall design: Triplicate samples of SqCC/Y1 cells were treated with combinations of DMSO, Pictilisib, and IFNg.